Arcutis Biotherapeutics Inc Revenue Growth Rates (ARQT), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Arcutis Biotherapeutics Inc   (NASDAQ: ARQT)
 

ARQT's Revenue Growth by Quarter and Year

Arcutis Biotherapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ARQT Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 129.86
1st Quarter March 105.40
FY 235.26





ARQT Revenue second quarter 2026 Y/Y Growth Comment
Arcutis Biotherapeutics Inc reported Revenue rise of 59.34% year on year in the second quarter 2026, to $ 129.86 millions, this is lower than Arcutis Biotherapeutics Inc 's recent average Revenue surge of 226.33%.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 61 other companies have achieved higher Revenue growth. While Arcutis Biotherapeutics Inc ' s Revenue jump of 59.34% ranks overall at the positon no. 702 in the second quarter 2026.


ARQT Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 81.47 % 427.42 % 357.09 %
3rd Quarter September - 121.67 % 17.45 % 5120.55 %
2nd Quarter June 59.34 % 164.1 % 494.61 % -
1st Quarter March 60.06 % 32.84 % 1683.09 % -
FY   - 91.34 % 229.73 % -

Financial Statements
Arcutis Biotherapeutics Inc 's second quarter 2026 Revenue $ 129.86 millions ARQT's Income Statement
Arcutis Biotherapeutics Inc 's second quarter 2025 Revenue $ 81.50 millions Quarterly ARQT's Income Statement


ARQT Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 30.52 % 59.43 % -64.5 %
3rd Quarter September - 21.74 % 45.04 % 634.3 %
2nd Quarter June 23.21 % 23.77 % -37.74 % 86.69 %
1st Quarter March -18.61 % -7.72 % 266.37 % -6.08 %
FY (Year on Year)   - 91.34 % 229.73 % -


Back to ARQT Growth rate Comparisons >> Back to ARQT Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #62
Healthcare Sector #146
Overall #702

Revenue Y/Y Growth Statistics
High Average Low
1032.9 % 226.33 % 76.11 %
(Jun 30 2024)   (Jun 30 2026)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #62
Healthcare Sector #146
Overall #702
Revenue Y/Y Growth Statistics
High Average Low
1032.9 % 226.33 % 76.11 %
(Jun 30 2024)   (Jun 30 2026)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Arcutis Biotherapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
634.28 % 90.99 % -64.51 %
(Sep 30 2023)  


ARQT's II. Quarter Q/Q Revenue Comment
Arcutis Biotherapeutics Inc achieved in the II. Quarter 2026 below company average Revenue jump of 23.21% quarter on quarter, to $ 129.86 millions.

Within Major Pharmaceutical Preparations industry 45 other companies have achieved higher Revenue quarter on quarter growth. While Arcutis Biotherapeutics Inc 's Revenue growth quarter on quarter, overall rank is 456.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #46
Healthcare Sector #96
Overall #456
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #46
Healthcare Sector #96
Overall #456
Revenue Q/Q Growth Statistics
High Average Low
634.28 % 90.99 % -64.51 %
(Sep 30 2023)  


ARQT's II. Quarter Q/Q Revenue Comment
Arcutis Biotherapeutics Inc achieved in the II. Quarter 2026 below company average Revenue jump of 23.21% quarter on quarter, to $ 129.86 millions.

Within Major Pharmaceutical Preparations industry 45 other companies have achieved higher Revenue quarter on quarter growth. While Arcutis Biotherapeutics Inc 's Revenue growth quarter on quarter, overall rank is 456.


Arcutis Biotherapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 463.98 $ 415.62 $ 376.07 $ 317.93 $ 263.47
Y / Y Revenue Growth (TTM) 76.11 % 95.29 % 91.34 % 129.21 % 99.5 %
Year on Year Revenue Growth Overall Ranking # 161 # 64 # 19 # 8 # 5
Seqeuential Revenue Change (TTM) 11.63 % 10.52 % 18.29 % 20.67 % 23.8 %
Seq. Revenue Growth (TTM) Overall Ranking # 702 # 304 # 1676 # 328 # 151


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Arcutis Biotherapeutics Inc 's cumulative twelve months Revenue were $ 464 millions, company would post below average annual Revenue growth of 23.8% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Arcutis Biotherapeutics Inc 's Revenue growth from the 105.4% growth in Mar 31 2026.

In the Healthcare sector 47 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 64 to 161.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 62
Healthcare Sector # 48
Overall # 161

Revenue TTM Y/Y Growth Statistics
High Average Low
1032.9 %
 226.33 %
76.11 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 62
Sector # 146
S&P 500 # 702
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Arcutis Biotherapeutics Inc 's cumulative twelve months Revenue were $ 464 millions, company would post below average annual Revenue growth of 76.11% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Arcutis Biotherapeutics Inc 's Revenue growth from the 105.4% growth in Mar 31 2026.

In the Healthcare sector 47 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 64 to 161.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 62
Healthcare Sector # 48
Overall # 161

Revenue TTM Y/Y Growth Statistics
High Average Low
1032.9 %
226.33 %
76.11 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 62
Sector # 146
S&P 500 # 702




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ARQT's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Mobia Medical Inc 102.35%$ 102.352 millions
Ptc Therapeutics inc 101.55%$ 101.548 millions
Eton Pharmaceuticals Inc 98.63%$ 98.631 millions
Immunitybio inc 93.91%$ 93.907 millions
Syndax Pharmaceuticals Inc 91.76%$ 91.759 millions
Phathom Pharmaceuticals Inc 88.02%$ 88.021 millions
Fennec Pharmaceuticals Inc 85.18%$ 85.184 millions
Alamar Biosciences Inc 82.08%$ 82.075 millions
Seastar Medical Holding Corp81.95%$ 81.953 millions
Sera Prognostics Inc 76.47%$ 76.471 millions
Innovative Eyewear Inc 74.46%$ 74.459 millions
Madrigal Pharmaceuticals Inc 71.17%$ 71.169 millions
Tg Therapeutics Inc 70.27%$ 70.272 millions
Tarsus Pharmaceuticals Inc 69.41%$ 69.406 millions
Hyperfine Inc 67.70%$ 67.698 millions
Alnylam Pharmaceuticals Inc 66.86%$ 66.856 millions
Emergent Biosolutions Inc 66.29%$ 66.288 millions
Vivos Therapeutics Inc 65.69%$ 65.691 millions
Iovance Biotherapeutics inc 65.65%$ 65.654 millions
Billiontoone Inc 64.40%$ 64.403 millions
Anteris Technologies Global Corp 63.27%$ 63.269 millions
Nexgel Inc 63.24%$ 63.242 millions
Carlsmed Inc 59.58%$ 59.575 millions
Sonoma Pharmaceuticals Inc 59.55%$ 59.552 millions
Arcutis Biotherapeutics Inc 59.33%$ 59.331 millions
Nephros Inc 58.55%$ 58.551 millions
Bioadaptives Inc 54.95%$ 54.955 millions
Zevra Therapeutics Inc 53.25%$ 53.251 millions
Beyond Air Inc 52.94%$ 52.941 millions
Caredx Inc 52.23%$ 52.226 millions


About Arcutis Biotherapeutics Inc Revenue Growth Rates (ARQT), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Arcutis Biotherapeutics Inc (CIK 1787306).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001787306-26-000051
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Arcutis Biotherapeutics Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.